Findings indicate a substantial reduction in breast and ovarian cancer incidence and mortality among BRCA1/2 carriers following RRS, particularly mastectomy and oophorectomy, compared to chemoprevention. This evidence concerns the gene BRCA1 and ovarian carcinoma.